Clinical phenotyping: role in treatment decisions in sarcoidosis
A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection. The authors participated in a Delphi expert consensus panel to develop a proposed phenotype categorisation and treatment recommendations for p...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2020-03-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/29/155/190145.full |
| _version_ | 1823934477538164736 |
|---|---|
| author | Robert P. Baughman Mary Beth Scholand Franck F. Rahaghi |
| author_facet | Robert P. Baughman Mary Beth Scholand Franck F. Rahaghi |
| author_sort | Robert P. Baughman |
| collection | DOAJ |
| description | A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection. The authors participated in a Delphi expert consensus panel to develop a proposed phenotype categorisation and treatment recommendations for pulmonary sarcoidosis patients. Panellists reached consensus that asymptomatic patients with normal pulmonary function and adenopathy alone or normal chest imaging do not require therapy, while symptomatic patients with impaired pulmonary function or infiltrates should be treated. The panel did not reach consensus on asymptomatic patients with abnormal chest imaging or reduced pulmonary function, or symptomatic patients with normal chest imaging and pulmonary function. The proposed phenotype categories and associated treatment recommendations are asymptomatic (no therapy), acute (disease duration <1–2 years, apparently self-limited, corticosteroids), chronic (antimetabolites and other second-line therapies) and advanced (biologics). Some clinical settings, such as dyspnoea/hypoxaemia at rest, severely impaired or rapidly decreasing pulmonary function tests, and severe cardiac, neurologic, ocular or renal involvement warrant immediate therapy. |
| first_indexed | 2024-12-16T22:20:51Z |
| format | Article |
| id | doaj.art-3a7800b4cefa47ec9cd91a9d6b585efc |
| institution | Directory Open Access Journal |
| issn | 0905-9180 1600-0617 |
| language | English |
| last_indexed | 2024-12-16T22:20:51Z |
| publishDate | 2020-03-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | European Respiratory Review |
| spelling | doaj.art-3a7800b4cefa47ec9cd91a9d6b585efc2022-12-21T22:14:01ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172020-03-012915510.1183/16000617.0145-20190145-2019Clinical phenotyping: role in treatment decisions in sarcoidosisRobert P. Baughman0Mary Beth Scholand1Franck F. Rahaghi2 University of Cincinnati Medical Center, Cincinnati, OH, USA University of Utah Medical Center, Salt Lake City, UT, USA Cleveland Clinic Florida, Weston, FL, USA A variety of phenotypic categorisations have been developed for sarcoidosis. Phenotyping has been used for genetics studies and to guide treatment selection. The authors participated in a Delphi expert consensus panel to develop a proposed phenotype categorisation and treatment recommendations for pulmonary sarcoidosis patients. Panellists reached consensus that asymptomatic patients with normal pulmonary function and adenopathy alone or normal chest imaging do not require therapy, while symptomatic patients with impaired pulmonary function or infiltrates should be treated. The panel did not reach consensus on asymptomatic patients with abnormal chest imaging or reduced pulmonary function, or symptomatic patients with normal chest imaging and pulmonary function. The proposed phenotype categories and associated treatment recommendations are asymptomatic (no therapy), acute (disease duration <1–2 years, apparently self-limited, corticosteroids), chronic (antimetabolites and other second-line therapies) and advanced (biologics). Some clinical settings, such as dyspnoea/hypoxaemia at rest, severely impaired or rapidly decreasing pulmonary function tests, and severe cardiac, neurologic, ocular or renal involvement warrant immediate therapy.http://err.ersjournals.com/content/29/155/190145.full |
| spellingShingle | Robert P. Baughman Mary Beth Scholand Franck F. Rahaghi Clinical phenotyping: role in treatment decisions in sarcoidosis European Respiratory Review |
| title | Clinical phenotyping: role in treatment decisions in sarcoidosis |
| title_full | Clinical phenotyping: role in treatment decisions in sarcoidosis |
| title_fullStr | Clinical phenotyping: role in treatment decisions in sarcoidosis |
| title_full_unstemmed | Clinical phenotyping: role in treatment decisions in sarcoidosis |
| title_short | Clinical phenotyping: role in treatment decisions in sarcoidosis |
| title_sort | clinical phenotyping role in treatment decisions in sarcoidosis |
| url | http://err.ersjournals.com/content/29/155/190145.full |
| work_keys_str_mv | AT robertpbaughman clinicalphenotypingroleintreatmentdecisionsinsarcoidosis AT marybethscholand clinicalphenotypingroleintreatmentdecisionsinsarcoidosis AT franckfrahaghi clinicalphenotypingroleintreatmentdecisionsinsarcoidosis |